Self-limited neonatal epilepsy (SeLNE) is a genetic neonatal epilepsy syndrome in which focal seizures begin in an otherwise well newborn, usually during the first days of life, and then remit during infancy. The most common genetic causes involve KCNQ2 and KCNQ3.
The word “self-limited” describes the usual seizure course. It does not mean that every neonatal seizure can safely be assumed to be benign, and acute causes such as stroke, infection, hypoglycaemia and brain injury must still be excluded.
Typical seizure onset
In classic KCNQ2-related self-limited neonatal epilepsy, seizures often begin between the second and eighth day after a term birth.
A seizure-free interval after birth is typical. Seizures beginning immediately at birth or in an unwell newborn should heighten concern for an acute symptomatic cause.
What the seizures look like
Neonatal seizures usually have focal onset. They may include tonic stiffening, clonic movements, autonomic changes, apnoea or cyanosis.
Video-EEG can show focal onset with spread or migration during the seizure.
Why EEG is particularly important in newborns
Neonatal seizures can be difficult to identify from movement alone, and some seizures are electrographic-only.
The ILAE neonatal classification therefore gives EEG a central role. Clinical events without an EEG correlate may represent non-epileptic neonatal movements rather than seizures.
EEG between seizures
The background EEG is usually normal or becomes normal as seizures settle in self-limited neonatal epilepsy.
A persistently severely abnormal background, burst suppression or marked multifocal abnormalities raise concern for a developmental and epileptic encephalopathy instead.
MRI and investigation for acute causes
Because seizures in a newborn are often provoked by an acute brain or systemic disorder, clinicians usually investigate for hypoxic-ischaemic injury, stroke, haemorrhage, infection, metabolic disturbance and structural brain abnormalities.
Normal development, normal examination and a typical family or genetic pattern support SeLNE only after these alternatives have been considered.
KCNQ2
KCNQ2 encodes a voltage-gated potassium-channel subunit that helps stabilise neuronal electrical activity.
Pathogenic variants can produce a wide spectrum, from self-limited neonatal epilepsy to severe KCNQ2 developmental and epileptic encephalopathy. The gene result therefore has to be interpreted together with the clinical phenotype.
KCNQ3
KCNQ3 can cause a clinically similar self-limited neonatal epilepsy, though it is less common than KCNQ2.
Newer reports continue to broaden the range of developmental outcomes associated with particular KCNQ3 variants, showing why “self-limited” should not be assumed from the gene name alone.
Family history
The syndrome is often autosomal dominant, and multiple relatives may have had neonatal seizures that stopped in infancy.
However, incomplete penetrance occurs, and a pathogenic variant may also arise de novo. Absence of an obvious family history therefore does not exclude the diagnosis.
Treatment
Acute neonatal seizure treatment depends on seizure burden and the clinical situation. Some KCNQ2-related self-limited epilepsies respond well to sodium-channel-blocking antiseizure medicines.
Recent cohort data continue to support the value of prompt genetic diagnosis because it can help clinicians select more targeted therapy in KCNQ2-related neonatal epilepsy.
How long treatment continues
Because the epilepsy is self-limited, long-term antiseizure treatment is often unnecessary once seizures have remitted and the infant is stable.
The decision to stop treatment depends on EEG, diagnosis, seizure course and local neonatal neurology practice.
Development
Development is expected to be normal in classic SeLNE.
Developmental impairment, persistent abnormal neurological examination or continuing drug-resistant seizures should prompt reconsideration of the diagnosis and evaluation for a neonatal-onset developmental and epileptic encephalopathy.
Later seizures
A minority of people with KCNQ2-related self-limited neonatal epilepsy later develop febrile seizures or epilepsy in childhood, adolescence or adulthood.
Self-limited neonatal epilepsy therefore describes the neonatal syndrome rather than guaranteeing lifelong freedom from all future seizures.
Genetic counselling
When a pathogenic variant is inherited in an autosomal-dominant pattern, each child of an affected individual has a 50% chance of inheriting that variant.
Because severity can vary between variants and occasionally within families, genetic counselling should discuss phenotype as well as inheritance probability.
Worldwide access
Rapid genetic testing is not universally available. In many regions, diagnosis still depends on seizure timing, family history, EEG, examination and exclusion of acute causes.
Where genomic testing is available, rapid neonatal sequencing can shorten diagnostic uncertainty and reduce repeated investigations.
The central point
Self-limited neonatal epilepsy is a specific genetic epilepsy syndrome, not a label for any newborn whose seizures eventually stop. Acute symptomatic causes must be excluded, and the distinction from neonatal developmental and epileptic encephalopathy is clinically important.
Related reading
Epilepsy Syndromes →
Genetics & Epilepsy →
Acute Symptomatic and Provoked Seizures →
Sources
- ILAE — neonatal and infant epilepsy syndromes
- GeneReviews — KCNQ2-Related Disorders
- ILAE Genetic Literacy Series — self-limited familial epilepsies of neonatal age and infancy
- KCNQ2 neonatal epilepsy: prompt diagnosis and treatment — 2026 cohort
Medical note: seizures in a newborn require urgent assessment because many neonatal seizures have an acute and potentially serious cause.
Evidence checked: September 2026.